Get 50% OFF This Summer!

Advertisement
logo

Zenith Drugs

ZENITHDRUG
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Zenith Drugs Share price and Fundamental Analysis

View All Details
View All Details
Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior. Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior.
Company Incorporation2000
ChairmanNA
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
138.73
PE Ratio
13.13
Industry P/E
35.21
PEG Ratio
0
ROE
14.06%
ROCE
13.17%
ROA
6.66%
Total Debt (Cr)
39.54
Debt to Equity
0.58
Dividend Yield
0.62%
EPS
6.16
Book Value & P/B
36.28 x 2.23
Face Value
10
Outstanding Shares(Cr)
1.71
Current Ratio
3.01
EV to Sales
1.18

Stock Returns

1 Week+5.06%
1 Month-5.1%
6 Months-13.92%
1 Year+7.64%
3 Years-22.97%
5 Years-22.97%

CAGR

1 Year CAGR

Revenue Growth

+27.81%

Net Profit Growth

+87.21%

Operating Profit Growth

+63.55%

Dividend Growth

N/A

Stock Returns CAGR

+5.54%
no_data

No Stocks

Smart Score

2.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 69.98%

FIIs : 0.06%

DIIs : 0.00%

Public : 29.96%

Promoter
FII/FPI
DII
Public
FII Shareholding Decreased by 0.36% to 0.06% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Zenith Drugs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Zenith Drugs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Zenith Drugs Ltd was originally incorporated on November 15, 2000 as a Private Limited Company in the name of 'Zenith Drugs Private Limited' issued by the Registrar of Companies, in the State of Madhya Pradesh, Gwalior. Subsequently, Company was converted into Public Limited and consequently, the name of Company was changed to Zenith Drugs Limited' pursuance to issuance of a Fresh Certificate of Incorporation on September 13, 2023 by the Registrar of Companies, Gwalior.

Zenith are a reputable pharmaceutical manufacturing and trading unit based out from Indore. With a diverse portfolio of formulations, the Company is specialized in manufacturing affordable and high quality medicines to meet the needs of patients. The Company is mainly engaged in the business of manufacturing and Trading of Medicines. It offers a wide range of formulations in various forms such as: ORS Powder; Liquid Orals; Oinments; Liquid Externals and Capsules.

The Company was established in 2000 by the visionary founders, Late Shri Ramniklal Soni, and Mr. Mukesh Jain. Initially in 2001, Company started as a modest manufacturing house for oral and external formulations. However, recognizing the importance of quality and compliance, the Company swiftly shifted to a Schedule M GMP compliant unit in 2004 where it started the production of two lines which are liquid orals and ointments. In 2007, it expanded the product line by incorporating ORS Powder manufacturing into their operations. In 2016, the Company established present manufacturing facility, which holds WHO GMP certification. In 2019, it expanded the product line by introducing liquid externals and capsules.

The Company propose Initial Public Fresh Issue upto 42,92,000 Equity Shares.

Zenith Drugs Share Price

Zenith Drugs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Zenith Drugs Market Cap

Market capitalization of Zenith Drugs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Zenith Drugs is valued compared to its competitors.

Zenith Drugs PE Ratio

Zenith Drugs PE ratio helps investors understand what is the market value of each stock compared to Zenith Drugs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Zenith Drugs PEG Ratio

The PEG ratio of Zenith Drugs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Zenith Drugs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Zenith Drugs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Zenith Drugs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Zenith Drugs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Zenith Drugs Total Debt

Total debt of Zenith Drugs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Zenith Drugs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Zenith Drugs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Zenith Drugs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Zenith Drugs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Zenith Drugs Technical Analysis

Technical analysis of Zenith Drugs helps investors get an insight into when they can enter or exit the stock. Key components of Zenith Drugs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Zenith Drugs shares often struggle to rise above due to selling pressure.

Zenith Drugs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Zenith Drugs ’s financial health and profitability.

Zenith Drugs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Zenith Drugs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Zenith Drugs Financials

The financials of Zenith Drugs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Zenith Drugs Profit and Loss Statements

The profit and loss statement of Zenith Drugs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Zenith Drugs .

Zenith Drugs Balance Sheet

The balance sheet presents a snapshot of Zenith Drugs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Zenith Drugs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App